Your browser doesn't support javascript.
loading
A Novel GUCY2C-CD3 T-Cell Engaging Bispecific Construct (PF-07062119) for the Treatment of Gastrointestinal Cancers.
Mathur, Divya; Root, Adam R; Bugaj-Gaweda, Bozena; Bisulco, Stephanie; Tan, Xingzhi; Fang, Wei; Kearney, Jessica C; Lucas, Justin; Guffroy, Magali; Golas, Jonathan; Rohde, Cynthia M; Stevens, Chad; Kamperschroer, Cris; Kelleher, Kerry; Lawrence-Henderson, Rosemary F; Upeslacis, Erik; Yao, Johnny; Narula, Jatin; LaVallie, Edward R; Fernandez, Diane R; Buetow, Bernard S; Rosfjord, Edward; Bloom, Laird; King, Lindsay E; Tchistiakova, Lioudmila; Nguyen, Anhco; Sapra, Puja.
Afiliación
  • Mathur D; Pfizer WorldWide Research and Development (R&D), Pearl River, New York. divya.mathur@pfizer.com puja.sapra@pfizer.com.
  • Root AR; Pfizer WorldWide R&D, Cambridge, Massachusetts.
  • Bugaj-Gaweda B; Pfizer WorldWide Research and Development (R&D), Pearl River, New York.
  • Bisulco S; Pfizer WorldWide Research and Development (R&D), Pearl River, New York.
  • Tan X; Pfizer WorldWide Research and Development (R&D), Pearl River, New York.
  • Fang W; Pfizer WorldWide Research and Development (R&D), Pearl River, New York.
  • Kearney JC; Pfizer WorldWide Research and Development (R&D), Pearl River, New York.
  • Lucas J; Pfizer WorldWide Research and Development (R&D), Pearl River, New York.
  • Guffroy M; Pfizer WorldWide Research and Development (R&D), Pearl River, New York.
  • Golas J; Pfizer WorldWide Research and Development (R&D), Pearl River, New York.
  • Rohde CM; Pfizer WorldWide Research and Development (R&D), Pearl River, New York.
  • Stevens C; Pfizer WorldWide R&D, Andover, Massachusetts.
  • Kamperschroer C; Pfizer WorldWide R&D, Groton, Connecticut.
  • Kelleher K; Pfizer WorldWide R&D, Cambridge, Massachusetts.
  • Lawrence-Henderson RF; Pfizer WorldWide R&D, Andover, Massachusetts.
  • Upeslacis E; Pfizer WorldWide Research and Development (R&D), Pearl River, New York.
  • Yao J; Pfizer WorldWide Research and Development (R&D), Pearl River, New York.
  • Narula J; Pfizer WorldWide R&D, Cambridge, Massachusetts.
  • LaVallie ER; Pfizer WorldWide R&D, Cambridge, Massachusetts.
  • Fernandez DR; Pfizer WorldWide R&D, La Jolla, California.
  • Buetow BS; Pfizer WorldWide R&D, La Jolla, California.
  • Rosfjord E; Pfizer WorldWide Research and Development (R&D), Pearl River, New York.
  • Bloom L; Pfizer WorldWide R&D, Cambridge, Massachusetts.
  • King LE; Pfizer WorldWide R&D, Andover, Massachusetts.
  • Tchistiakova L; Pfizer WorldWide R&D, Cambridge, Massachusetts.
  • Nguyen A; Pfizer WorldWide Research and Development (R&D), Pearl River, New York.
  • Sapra P; Pfizer WorldWide Research and Development (R&D), Pearl River, New York. divya.mathur@pfizer.com puja.sapra@pfizer.com.
Clin Cancer Res ; 26(9): 2188-2202, 2020 05 01.
Article en En | MEDLINE | ID: mdl-31996389
Asunto(s)
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Linfocitos T / Neoplasias Colorrectales / Complejo CD3 / Anticuerpos Biespecíficos / Receptores de Enterotoxina / Neoplasias Gastrointestinales / Inmunoterapia Límite: Animals / Female / Humans Idioma: En Revista: Clin Cancer Res Asunto de la revista: NEOPLASIAS Año: 2020 Tipo del documento: Article
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Linfocitos T / Neoplasias Colorrectales / Complejo CD3 / Anticuerpos Biespecíficos / Receptores de Enterotoxina / Neoplasias Gastrointestinales / Inmunoterapia Límite: Animals / Female / Humans Idioma: En Revista: Clin Cancer Res Asunto de la revista: NEOPLASIAS Año: 2020 Tipo del documento: Article